India's Bajaj Healthcare surges, seeks compulsory license for COVID-19 drug

Bajaj Healthcare

29/06/2021 07:45

** Shares of pharmaceuticals maker Bajaj Healthcare (BHL)
 BAJH.BO  surges 19.96% to a record high of 863.95 rupees
    ** Co on Monday said https://www.bseindia.com/xml-data/corpfiling/AttachLive/8c78a3f5-1363-4ddf-a211-eff67ee7756b.pdf
 it has requested the Indian Patent Office to grant compulsory
license for manufacturing and supply of COVID-19 drug
"Baricitinib"
    ** Baricitinib, U.S.-based Eli Lily and Co's arthritis drug,
has been given restricted emergency use approval by India's drug
regulator for use in combination with remdesivir for the
treatment of hospitalised COVID-19 adult patients  urn:newsml:reuters.com:*:nL4N2MX0Y9
    ** In May, Eli Lilly had signed licensing agreements with
three Indian generic drugmakers to expand the availability of
Baricitinib in the country for treating COVID-19 patients 
    ** BHL says Eli Lily declined application from co seeking
voluntary license for manufacturing of Baricitinib and co has
moved to the Indian Patent Office, requesting to grant
compulsory licence for manufacture and supply 
    ** BHL stock on track to log its best session since Sept
    ** Around 441,169 shares change hands by 0629 GMT, vs 30-day
avg of 78,169 shares
    ** Stock up nearly 61.55% YTD, as of last close

 (Reporting by Chandini Monnappa in Bengaluru)
 ((Chandini.M@thomsonreuters.com))